Jenburkt Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
JENBURPH
Pharmaceuticals
Share Price BSE
₹1030.00
▼
-21.90 (-2.08%)
As of April 13, 2026, the Jenburkt Pharmaceuticals share price (BSE: JENBURPH) is ₹1,030.00, down 2.08% from the previous close, with shares trading between ₹1,022.10 and ₹1,050.00, and a 52-week range of ₹955.45–₹1,392.65.
Browse Jenburkt Pharmaceuticals annual reports to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Jenburkt Pharmaceuticals Market Cap
₹447.08 Cr.
JENBURPH P/E Ratio (TTM)
13.71
Jenburkt Pharmaceuticals P/B Ratio
2.43
EPS (TTM)
₹72.65
Dividend Yield
1.79%
Debt to Equity
0.01
JENBURPH 52 Week High
₹1392.65
Jenburkt Pharmaceuticals 52 Week Low
₹955.45
Operating Margin
24.00%
Profit Margin
18.50%
JENBURPH Revenue (TTM)
₹173.00
EBITDA
₹48.00
Net Income
₹32.00
Total Assets
₹196.00
Total Equity
₹172.00
Jenburkt Pharmaceuticals Share Price History - Stock Screener Chart
Screen JENBURPH historical share price movements with interactive charts. Analyze price trends and patterns.
Jenburkt Pharmaceuticals Company Profile - Fundamental Screener
Screen Jenburkt Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for JENBURPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE354A01013
Jenburkt Pharmaceuticals Balance Sheet Screener
Screen JENBURPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 196 | 165 | 142 | 143 | 121 | 104 | 103 | 78 | 76 | 58 |
| Current Assets | 57 | 110 | 81 | 76 | 80 | 90 | 90 | 66 | 64 | 45 |
| Fixed Assets | 15 | 10 | 10 | 11 | 11 | 12 | 10 | 10 | 11 | 12 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 6 | 4 | 4 | 4 | 5 | 5 | 3 | 3 | 4 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 172 | 145 | 122 | 117 | 99 | 80 | 78 | 61 | 54 | 40 |
| Share Capital | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 167 | 141 | 118 | 113 | 94 | 75 | 73 | 57 | 50 | 36 |
Jenburkt Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Jenburkt Pharmaceuticals income statement and profit fundamentals.
Analyze JENBURPH quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Jenburkt Pharmaceuticals share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173 | 158 | 147 | 142 | 129 | 114 | 123 | 126 | 118 | 106 | 96 | 87 |
| Expenses | 125 | 111 | 109 | 106 | 97 | 90 | 99 | 98 | 91 | 84 | 77 | 70 |
| EBITDA | 48 | 47 | 38 | 36 | 32 | 24 | 24 | 28 | 27 | 23 | 19 | 17 |
| Operating Profit % | 24.00% | 27.00% | 23.00% | 22.00% | 22.00% | 18.00% | 17.00% | 20.00% | 21.00% | 19.00% | 18.00% | 18.00% |
| Depreciation | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 3 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 45 | 44 | 35 | 33 | 30 | 22 | 21 | 27 | 25 | 21 | 17 | 14 |
| Tax | 13 | 12 | 9 | 8 | 8 | 5 | 6 | 7 | 8 | 7 | 6 | 5 |
| Net Profit | 32 | 32 | 26 | 25 | 22 | 17 | 15 | 20 | 17 | 14 | 11 | 10 |
| EPS | 73.50 | 72.65 | 58.86 | 53.90 | 48.58 | 35.96 | 32.40 | 43.14 | 37.50 | 29.05 | 23.18 | 20.75 |
Jenburkt Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen JENBURPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 28 | 8 | 17 | 9 | 20 | 15 | 13 | 16 | 10 | 8 |
| Investing Activities | -17 | -1 | 3 | -1 | -19 | -3 | -11 | 1 | -10 | 0 |
| Financing Activities | -8 | -7 | -21 | -6 | -1 | -11 | -2 | -18 | 1 | -5 |
| Net Cash Flow | 3 | 1 | -1 | 3 | 0 | 1 | 0 | -1 | 1 | 2 |
Jenburkt Pharmaceuticals Shareholding Pattern Screener
See Jenburkt Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Jenburkt Pharmaceuticals promoter holding and ownership changes for JENBURPH on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.68% | 46.67% | 46.66% | 46.65% | 47.23% | 46.71% | 46.71% | 46.69% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.12% | 0.12% | 0.12% | 0.12% | 0.00% | 0.00% | 0.00% | 0.12% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 43.55% | 43.32% | 43.26% | 43.13% | 42.65% | 43.39% | 43.56% | 43.43% |
| Other Holding | 9.66% | 9.89% | 9.97% | 10.10% | 10.11% | 9.90% | 9.73% | 9.76% |
| Shareholder Count | 6,987 | 6,712 | 6,855 | 7,163 | 6,316 | 6,419 | 6,628 | 6,901 |
Jenburkt Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Jenburkt Pharmaceuticals dividend history with payout and yield data.
View Jenburkt Pharmaceuticals dividend details including ex-dates and amounts for JENBURPH stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹18.00 | 1.88% |
| 2024-March | ₹15.30 | 1.51% |
| 2023-March | ₹14.40 | 2.09% |
| 2022-March | ₹12.00 | 1.82% |
| 2021-March | ₹10.20 | 1.80% |
| 2020-March | ₹8.10 | 2.03% |
| 2019-March | ₹10.20 | 3.21% |
| 2018-March | ₹9.00 | 1.78% |
| 2017-March | ₹8.10 | 1.32% |
Jenburkt Pharmaceuticals Stock Index Membership
See which indices include Jenburkt Pharmaceuticals stock.
Check JENBURPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Jenburkt Pharmaceuticals Market Events Screener - Corporate Actions
Get Jenburkt Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Jenburkt Pharmaceuticals stock events that may affect JENBURPH share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | -2.87% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | 0.91% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -9.73% |
| 2025-07-18 | 2025-07-18 | Annual General Meeting | NA | 18.69% |
| 2025-07-11 | 2025-07-11 | Dividend | ₹ 18.00 /share | 25.87% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 9.69% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -6.60% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | 7.15% |
| 2024-07-30 | 2024-07-30 | Annual General Meeting | NA | 16.63% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 15.30 /share | 8.04% |
| 2023-07-19 | 2023-07-20 | Dividend | ₹ 14.40 /share | 3.72% |
| 2022-07-21 | 2022-07-23 | Dividend | ₹ 12.00 /share | -7.44% |
| 2021-08-30 | Dividend | ₹ 10.20 /share | -9.37% |
Jenburkt Pharmaceuticals Competitors Screener - Peer Comparison
Screen JENBURPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Jenburkt Pharmaceuticals Company Announcements - News Screener
Screen JENBURPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-23 | Closure of Trading Window | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-03 | Standalone Unaudited Financial Results For The Quarter And Nine Months Ended On 31St December 2025. | - |
| 2026-02-03 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 03Rd February 2026. | - |
| 2026-01-28 | Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter And Nine Months Ended On 31St December 2025. | - |
| 2026-01-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-15 | Closure of Trading Window | - |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-10-28 | Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2025. | - |
| 2025-10-28 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 28Th October 2025. | - |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-10-03 | Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2025. | - |
| 2025-09-22 | Closure of Trading Window | - |
| 2025-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-08-12 | Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2025. | - |
| 2025-08-12 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 12Th August 2025. | - |
| 2025-08-01 | Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2025. | - |
| 2025-07-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-07-18 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-07-18 | Proceedings Of The 40Th Annual General Meeting Of The Company Held On Today I.E. 18Th July 2025. | - |